Back to top
more

CanFite Biopharma (CANF)

(Delayed Data from AMEX)

$1.99 USD

1.99
49,180

-0.08 (-3.86%)

Updated Nov 14, 2024 03:59 PM ET

After-Market: $1.99 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 250)

Industry: Medical - Drugs

Zacks News

KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys

The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.

Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark

Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss

Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.

Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue

Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.

Tilray (KL) Looks Good: Stock Adds 5.3% in Session

Tilray (KL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Top Ranked Momentum Stocks to Buy for April 28th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 28th

Top Ranked Momentum Stocks to Buy for April 27th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th

Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment

Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

Company News For Jan 6, 2020

Companies In The News Are: CANF, LW, INCY, NOVN

Company News For Dec 27, 2019

Companies In The News Are: QGEN, IMMU, CANF, SBPH

All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy

Can-Fite (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.